Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.

Rhea-AI Summary

BioArctic (NYSE:B) reports that the FDA extended the PDUFA date for the sBLA for Leqembi Iqlik to August 24, 2026 after requesting additional information, which the agency classified as a major amendment and added a three‑month review period. The FDA has not raised approvability concerns to date.

Leqembi maintenance subcutaneous dosing received FDA action on August 26, 2025, and Leqembi is approved by more than 50 regulatory authorities worldwide. BioArctic and Eisai continue plans for joint Nordic commercialization.

Positive

• Leqembi approved by more than 50 regulatory authorities worldwide
• FDA has not raised approvability concerns to date for Leqembi Iqlik
• Subcutaneous maintenance dosing received FDA action on August 26, 2025

Negative

• FDA extended the PDUFA action date to August 24, 2026 after a major amendment
• Review extended by three months, delaying potential start‑dose approval timing

News Market Reaction – B

+3.08%

+3.08% Session close to close

In the May 8 session, B gained 3.08%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement clarifies the U.S. regulatory timetable for the subcutaneous Leqembi Iqlik regimen...

Analysis

This announcement clarifies the U.S. regulatory timetable for the subcutaneous Leqembi Iqlik regimen, with the PDUFA action date now set for August 24, 2026 after a three‑month review extension. The FDA has not raised approvability concerns to date, and Leqembi already holds approvals from more than 50 regulators worldwide. Investors may monitor future FDA communications, regional commercialization plans, and how this regimen complements the previously approved maintenance dosing from August 26, 2025.

Key Figures

New PDUFA date: August 24, 2026 Review extension: 3 months Maintenance approval date: August 26, 2025 +2 more

5 metrics

New PDUFA date August 24, 2026 Updated FDA action date for Leqembi Iqlik sBLA

Review extension 3 months FDA extension of sBLA review period

Maintenance approval date August 26, 2025 FDA approval of subcutaneous maintenance dosing regimen

Global approvals more than 50 regulators Leqembi approvals worldwide

Dosing frequency once weekly Subcutaneous Leqembi Iqlik injection regimen

Historical Context

5 past events · Latest: Apr 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 28	Asset IPO plan	Positive	-3.7%	Announced management team and minority IPO for North American gold assets.
Apr 27	Distribution/listing	Neutral	-1.0%	Detailed distribution and dual-listing timeline for Octave Intelligence shares.
Apr 21	Annual report 2025	Positive	-5.8%	Reported breakthrough Alzheimer’s drug, broad pipeline and record-high 2025 profits.
Apr 15	Tech/ESG initiative	Positive	-1.7%	Launched Green Cubes digital twin mapping for South American mining reclamation.
Apr 10	Earnings date set	Neutral	+2.6%	Scheduled first quarter 2026 results release and webcast on May 11.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows several instances where ostensibly positive corporate or asset updates were followed by negative 24-hour price reactions.

Recent Company History

Over the last month, news has focused on portfolio moves, strategic disclosures and performance. On Apr 28, 2026, an IPO plan for North American gold assets with ~2.0 Moz 2025 output was followed by a -3.69% move. An annual report highlighting a breakthrough Alzheimer’s drug and record-high 2025 profits on Apr 21, 2026 preceded a -5.84% reaction. Other items, including an earnings date announcement and technology deployment in mining, saw more moderate stock responses.

Key Terms

supplemental biologics license application, pdufa, subcutaneous

3 terms

supplemental biologics license application regulatory

"for the supplemental Biologics License Application (sBLA) for a once weekly"

A supplemental biologics license application is a formal request to a regulator (such as the U.S. Food and Drug Administration) asking permission to change an already approved biological product — for example to add a new use, change how it’s made, or alter dosing. For investors, an approved supplemental application can expand a product’s sales or reduce manufacturing risk, while a delay or rejection can limit revenue prospects or raise compliance costs; think of it like applying for an update to a building permit for an existing, income-producing property.

pdufa regulatory

"The new Prescription Drug User Fee Act (PDUFA) action date is August 24, 2026."

PDUFA is the Prescription Drug User Fee Act, the U.S. law under which drug companies pay fees that fund the FDA's review of new medicines. In company news the term usually appears as the PDUFA date, the target deadline by which the FDA aims to decide on a drug application; that date tells investors when to expect the approval or rejection decision for the product.

subcutaneous medical

"for a once weekly lecanemab irmb subcutaneous injection, also known as"

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, May 8, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection, also known as Leqembi® Iqlik™, as a starting dose for the treatment of early Alzheimer's disease. The new Prescription Drug User Fee Act (PDUFA) action date is August 24, 2026. 

As part of the ongoing review process, the agency requested additional information and has determined that it constituted a major amendment to the sBLA, extending the PDUFA date to allow sufficient time for a full review of the additional materials. The FDA has not raised any concerns to date regarding the approvability of Leqembi Iqlik as a starting dose.

Eisai believes that the comprehensive clinical data package evaluating subcutaneous administration of Leqembi across multiple studies and dosing regimens strongly supports the potential use of Leqembi Iqlik for initiation therapy, following FDA approval of the subcutaneous maintenance dosing regimen on August 26, 2025.

Leqembi has been approved by more than 50 regulatory authorities worldwide, reflecting broad regulatory confidence in Leqembi as a treatment option for early Alzheimer's disease.

Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for clinical development, marketing authorization applications and commercialization of Leqembi for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai, and the two companies are currently preparing for a joint commercialization in the region.  

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on April 29, 2026, at 8:30 CET.

For further information, please contact: 
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180

Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08

About Leqembi^® (lecanemab)
Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Leqembi is approved in 53 countries and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 7 countries, including the United Kingdom, China, the US and Japan, and applications have been filed in 10 countries and regions. In the US, Leqembi Iqlik™ is approved for subcutaneous dosing with an autoinjector for maintenance treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. In January 2026, Eisai's supplemental Biologics License Application regarding a subcutaneous starting dose with Leqembi Iqlik was granted Priority Review by the US FDA with a May 24, 2026, PDUFA date. In January 2026, the Biologics License Application for subcutaneous formulation of Leqembi was accepted in China and in February, the application was designated for priority review.

Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

Please find full Prescribing Information for Leqembi here.

About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/leqembi--iqlik--pdufa-date-updated-to-august-24-in-the-u-s-,c4346314

The following files are available for download:

https://mb.cision.com/Main/9978/4346314/4084021.pdf

Leqembi® Iqlikâ„¢ PDUFA date updated to August 24 in the U.S.

 

View original content:https://www.prnewswire.com/news-releases/leqembi-iqlik-pdufa-date-updated-to-august-24-in-the-us-302766719.html

SOURCE BioArctic

FAQ

What is the new PDUFA date for Leqembi Iqlik (B)?

The FDA set the new PDUFA date to August 24, 2026. According to BioArctic, the date moved after the agency classified submitted additional information as a major amendment requiring more time for review.

Why did the FDA extend the review for Leqembi Iqlik (B)?

The FDA requested additional information that it deemed a major amendment, extending the review. According to BioArctic, the extension allows sufficient time for a full review of those additional materials.

Has the FDA raised concerns about approvability of Leqembi Iqlik (B)?

No, the FDA has not raised approvability concerns to date for Leqembi Iqlik. According to BioArctic, the agency has continued review but requested more data classified as a major amendment.

What regulatory progress has Leqembi achieved globally (B)?

Leqembi is approved by more than 50 regulatory authorities worldwide. According to BioArctic, that reflects broad regulatory acceptance for Leqembi as a treatment option for early Alzheimer’s disease.

How does this extension affect BioArctic and Eisai's Nordic commercialization plans (B)?

BioArctic and Eisai are preparing joint commercialization in the Nordic region despite the extension. According to BioArctic, partnership and commercialization planning in the Nordics continue while the U.S. review proceeds.